Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory AML Refractory AML is defined as follows;~  1. Primary refractory: failure to achieve complete remission (CR) after 2 cycles of induction chemotherapy; or, in patient ≥65 years of age, progressive AML after treatment with hypomethylating agent (increase in peripheral blood blast by 50% or increase in bone marrow blast by 25%)~ 2. Relapse then refractory: recurrence of AML, which is refractory to standard salvage chemo therapy; or, in patient ≥65 years of age, to hypomethylating agent~ 3. AML in ≥2 relapses~* Patients should be 19 years of age or older~* Patients should have Karnofsky performance scale ≥70~* Patients and cell donors must understand fully and sign informed consent forms~Exclusion Criteria:~* Pregnant or lactating women~* Patient with abnormal liver function (total bilirubin ≥ 5.0 mg/dl, AST ≥ 5 times upper normal limits)~* Patients with abnormal renal function (creatinine ≥ 3.0 mg/dl)~* Patients with clinically-evident cardiac or pulmonary dysfunction~* Patients with infection that is progressive despite appropriate anti-microbial treatment~* Patients with hypersensitivity to gentamicin~* Patients who had received allogeneic cell therapy previously.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- treatment (Type: EXPERIMENTAL): patients will receive donor-derived NK cell infusion after haploidentical HCT
- control (Type: NO_INTERVENTION): patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT

Based on this trial design, predict the completion outcome and termination type (if applicable).